Explore the latest developments concerning LLY Up Around.
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Eli Lilly and Company's LLY stock has risen 5.8% since it announced solid second-quarter results on Aug. 5. Lilly's earnings and revenues comfortably exceeded estimates. Revenues rose 48% year over year to $22.97 billion while adjusted EPS rose 33% to $8.38.
Mounjaro and Zepbound remained the primary growth engines, with both drugs beating their respective consensus estimates. Newer medicines also made meaningful contributions across immunology, oncology and neuroscience. The company also raised its sales expectations for the second time this year.
However, a single quarter's results are not so important for long-term investors. To make an informed decision on whether to buy, sell or hold the stock, it is important to evaluate the company's fundamentals by examining its key strengths and weaknesses.
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.
Eli Lilly (LLY) is delivering a blockbuster performance, powered by its dominant obesity and diabetes drugs. The stock has returned +80% over the last twelve months, and with shares trading around $1180.16, it’s a titan in the healthcare space. Yet when you line it up with its peers, a strange mismatch appears.
On a trailing GAAP basis, Merck trades at an optically elevated 105.7 times earnings—a figure distorted by recent acquisition-related charges and one-off items that compressed its net income—compared to Lilly’s 39.4 times earnings. Even on an adjusted operating basis, however, Lilly’s 50% top-line expansion contrasts sharply with Merck’s 4.6% growth, underscoring how differently the market is pricing the two trajectories.
DayPlus Cordless Pressure Washer, 3000PSI Portable High Pressure Washer, Lightweight Jet Wash with Adjustable 6 in 1 Nozzle
Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity
LLY earns a BUY at a $1,415.89 price target (20% upside), with retatrutide's Q1 2027 BLA submission capable of pushing shares to $1,627.
Novo Nordisk earnings contracted 21% YoY while Merck trades at 50x forward earnings on just 5% revenue growth, making Lilly's 32x multiple look earned.
The most widely read finance newsletter on Substack isn't published by a bank, it's Doomberg, where 383,000+ readers get the energy and macro analysis the mainstream press misses. 24/7 Wall St. readers save 17% on their first year here.
Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next. Retatrutide, orforglipron, and a stacked oncology and neuroscience bench point to a growth runway that our proprietary model believes justifies a materially higher stock price over the next twelve months.
For more detailed information, explore updates concerning LLY Up Around.
0 Comments